CRISPR Therapeutics AG (NASDAQ:CRSP) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. BofA is Bullish on CRISPR Therapeutics AG (CRSP)On January 22, 2026, TheFly disclosed that Alec Stranahan, a BofA analyst. It reduced the price objective for CRISPR Therapeutics AG (NASDAQ:CRSP) from $90 to $89 and retained a buy rating. CRISPR Therapeutics AG (NASDAQ:CRSP) separately announced its planned 2026 milestones and strategic priorities on January 12, 2026. CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing firm.